Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 5 | 2017 | 408 | 0.710 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2017 | 228 | 0.670 |
Why?
|
| Tuberculosis | 3 | 2016 | 536 | 0.580 |
Why?
|
| Sputum | 3 | 2016 | 117 | 0.500 |
Why?
|
| Postpericardiotomy Syndrome | 1 | 2016 | 4 | 0.500 |
Why?
|
| Pleural Effusion | 1 | 2016 | 106 | 0.460 |
Why?
|
| Antitubercular Agents | 3 | 2016 | 264 | 0.420 |
Why?
|
| Population Surveillance | 1 | 2016 | 392 | 0.400 |
Why?
|
| Feces | 1 | 2015 | 700 | 0.370 |
Why?
|
| Asthma | 3 | 2004 | 761 | 0.270 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2016 | 382 | 0.250 |
Why?
|
| Life Support Care | 1 | 2005 | 48 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 106 | 0.220 |
Why?
|
| Brain Death | 1 | 2005 | 76 | 0.220 |
Why?
|
| Goiter | 1 | 2003 | 8 | 0.200 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2003 | 9 | 0.200 |
Why?
|
| Bronchoscopy | 2 | 2018 | 176 | 0.180 |
Why?
|
| Heart Arrest | 1 | 2005 | 358 | 0.170 |
Why?
|
| Radiography, Thoracic | 2 | 2017 | 146 | 0.170 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 45 | 0.170 |
Why?
|
| Clinical Deterioration | 1 | 2020 | 12 | 0.170 |
Why?
|
| Patient Handoff | 1 | 2020 | 22 | 0.170 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 537 | 0.160 |
Why?
|
| Bronchial Neoplasms | 1 | 2018 | 14 | 0.140 |
Why?
|
| Tracheal Neoplasms | 1 | 2018 | 20 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2018 | 62 | 0.140 |
Why?
|
| Leiomyoma | 1 | 2018 | 73 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 391 | 0.130 |
Why?
|
| Pulmonary Atelectasis | 1 | 2017 | 13 | 0.130 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2017 | 43 | 0.130 |
Why?
|
| Bacterial Typing Techniques | 1 | 2017 | 100 | 0.130 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2016 | 64 | 0.120 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 85 | 0.110 |
Why?
|
| Rifampin | 1 | 2016 | 119 | 0.110 |
Why?
|
| Catheters, Indwelling | 1 | 2016 | 149 | 0.110 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 75 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 2021 | 0.110 |
Why?
|
| Weight Gain | 1 | 2016 | 375 | 0.110 |
Why?
|
| Humans | 19 | 2021 | 125613 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 2917 | 0.090 |
Why?
|
| Adult | 9 | 2021 | 30189 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 734 | 0.080 |
Why?
|
| Aza Compounds | 1 | 2009 | 14 | 0.080 |
Why?
|
| Directly Observed Therapy | 1 | 2008 | 25 | 0.070 |
Why?
|
| Isoniazid | 1 | 2009 | 65 | 0.070 |
Why?
|
| Critical Care | 2 | 2005 | 659 | 0.070 |
Why?
|
| Female | 11 | 2018 | 67790 | 0.070 |
Why?
|
| Quinolines | 1 | 2009 | 111 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2008 | 238 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2016 | 12334 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 1815 | 0.060 |
Why?
|
| Mediastinum | 1 | 2006 | 47 | 0.060 |
Why?
|
| Pregnancy | 3 | 2018 | 7391 | 0.060 |
Why?
|
| Histoplasmosis | 1 | 2006 | 54 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2008 | 347 | 0.060 |
Why?
|
| Male | 6 | 2016 | 61966 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 166 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 2507 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1103 | 0.050 |
Why?
|
| Safety | 1 | 2004 | 210 | 0.050 |
Why?
|
| Acute Disease | 2 | 2004 | 1038 | 0.050 |
Why?
|
| Obstetric Labor Complications | 1 | 2004 | 96 | 0.050 |
Why?
|
| Fluticasone | 1 | 2003 | 15 | 0.050 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2004 | 119 | 0.050 |
Why?
|
| Androstadienes | 1 | 2003 | 49 | 0.050 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2002 | 8 | 0.050 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2002 | 30 | 0.050 |
Why?
|
| Vasculitis | 1 | 2002 | 45 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 201 | 0.050 |
Why?
|
| Thyroidectomy | 1 | 2003 | 98 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 623 | 0.050 |
Why?
|
| Glomerulonephritis | 1 | 2002 | 76 | 0.050 |
Why?
|
| Middle Aged | 3 | 2016 | 27263 | 0.040 |
Why?
|
| Risk Factors | 1 | 2016 | 10346 | 0.040 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2005 | 330 | 0.040 |
Why?
|
| Young Adult | 1 | 2015 | 9556 | 0.040 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2021 | 25 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 485 | 0.040 |
Why?
|
| HIV Infections | 2 | 2008 | 1955 | 0.040 |
Why?
|
| Mycobacterium avium Complex | 1 | 2021 | 20 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2002 | 156 | 0.040 |
Why?
|
| Hospitals, County | 1 | 2020 | 22 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2003 | 353 | 0.040 |
Why?
|
| Hospital Rapid Response Team | 1 | 2020 | 35 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2021 | 16725 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2020 | 127 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 5079 | 0.040 |
Why?
|
| Aged | 1 | 2016 | 19970 | 0.030 |
Why?
|
| Heart Rate, Fetal | 1 | 2018 | 63 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 354 | 0.030 |
Why?
|
| South Africa | 1 | 2016 | 99 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 1998 | 276 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 968 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2016 | 35 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 132 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 235 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 1973 | 0.030 |
Why?
|
| Pneumocystis | 1 | 1995 | 9 | 0.030 |
Why?
|
| Texas | 2 | 2020 | 3531 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1995 | 35 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1995 | 150 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 412 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 484 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 2558 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 4878 | 0.020 |
Why?
|
| United States | 2 | 2016 | 11141 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2020 | 1163 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2009 | 97 | 0.020 |
Why?
|
| Histoplasma | 1 | 2006 | 37 | 0.020 |
Why?
|
| Arm | 1 | 2006 | 72 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1596 | 0.010 |
Why?
|
| Edema | 1 | 2006 | 144 | 0.010 |
Why?
|
| Fibrosis | 1 | 2006 | 393 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2006 | 302 | 0.010 |
Why?
|
| Pain | 1 | 2006 | 429 | 0.010 |
Why?
|
| Causality | 1 | 2002 | 89 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 5907 | 0.010 |
Why?
|
| Coronaviridae | 1 | 1998 | 4 | 0.010 |
Why?
|
| Urban Health | 1 | 1998 | 74 | 0.010 |
Why?
|
| Rhinovirus | 1 | 1998 | 60 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1998 | 50 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 601 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1998 | 449 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 1235 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1995 | 37 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 1415 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1995 | 168 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 1129 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1998 | 3645 | 0.000 |
Why?
|